GlassScriptPhysician profile
Kashmir Chatha Reeser
NPI 1851793848
$1,329.81
in general payments reported to CMS, 2019-2025
12 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $270 · 2024: $613 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $293.71 | 2023-2025 | Benlysta |
| Amgen INC. | $288.56 | 2024-2025 | Krystexxa, Uplizna, Tepezza |
| Astrazeneca Pharmaceuticals LP | $171.74 | 2023-2025 | Saphnelo, Farxiga |
| Abbott Laboratories | $125.00 | 2023 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $103.45 | 2023 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $73.09 | 2024-2025 | Orencia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.52 | 2025 | Xifaxan |
| Ucb, INC. | $66.57 | 2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $41.73 | 2025 | |
| Ardelyx, INC. | $36.08 | 2024-2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $33.18 | 2024 | Idacio |
| Janssen Biotech, INC. | $29.18 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashmir Reeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.